Flash I did not make an assumption. It clearly says data includes all evaluable patients. A dropped patient is not evaluable, being they have dropped from the trial.
Patients responding well, and patients not responding well, could have dropped out. Anavex did not control who dropped, so implying they are showing data without dropouts, you are also implying the dropouts were not responding, hence providing higher avgs and better results. Let's be real, if patients were taking 10ml doses, and they were taking 10ml doses, we would expect those patients to decline being we know it takes 14ml to receive positive benefit from 2-73, and, it's these patients who would most likely dropout being 2-73 was not helping them. So, it's very possible the dropouts were on low doses and continuing the AD decline, for different reasons dropped out of the trial, and in turn the data represented higher avgs on this particular graph.
Can I ask, what's your point here?
Market Data 
Markets 
AI
